Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ABCD = adiposity-based chronic disease; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACE = American College of Endocrinology; ACEI = angiotensin-converting enzyme inhibitor; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CGM = continuous glucose monitoring; CHD = coronary heart disease; CKD = chronic kidney disease; DKA = diabetic ketoacidosis; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density-lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low-density-lipoprotein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiologic evidence shows a continuous relationship between A1C and CVD and all-cause mortality.72”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [72]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cited by
Items 301–400 of 610
Validity of the Good Practice Guidelines: The example of type 2 diabetes
Tudrej, B. V., Favard, D., Vaillant-Roussel, H., Pouchain, D., Jaafari, N., & Boussageon, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108459 · Cited by 5
Lifestyle Medicine in Diabetes Care: The Lifedoc Health Model
Nieto-Martínez, R. E., Neira, C. P., de Oliveira, D., Rodriguez, A. E. V., Neira, A., Velásquez-Rodríguez, P., Garcia, G., Gonzalez-Rivas, J. P., Mechanick, J. I., & Velasquez‐Mieyer, P. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221103470 · Cited by 7
Self-citationTabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzík, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
“Current guidelines such as ADA/EASD and AACE support the concept of simplifying the treatment regimen to decrease treatment complexity and burden, particularly for insulin therapy, which may in turn improve adherence and glycaemic control [5, 7, 21, 92].”
BackgroundJoshi, N., Qasim, M. Z., Kanumilli, S., Shaukat, F., Kumar, A., Mahek, F., Khalid, S., Zeeshan, M., Shaik, M. Y., Nishat, S. M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002494 · Cited by 6
Tan, F. C. J. H., Ang, S. B., & Bee, Y. M. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2020464 · Cited by 5
Flory, J., Li, J., Dawwas, G. K., & Leonard, C. E. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.245 · Cited by 5
The Use of Continuous Glucose Monitoring in Older People With Type 2 Diabetes
Rao, H., Fakourfar, N., Sun, C., & Lewis, J. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.556 · Cited by 5
Abdelhamid, M., Kandil, H., Hassan, M. S., Shaheen, S. M., Sobhy, M. A., ElEtreby, A., Hasan‐Ali, H., Mahfouz, H., Nasr, G. M., Shawky, I., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13811 · Cited by 5
Chen, X., Jiang, H., Li, H., Kuang, H., Chen, L., Ma, J., Zhang, Q., Pan, T., Yang, W., & SUCCESS study investigators (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14873 · Cited by 6
Kalra, S., Bhattacharya, S., Dhingra, A., Das, S., Kapoor, N., Shaikh, S. S., Kolapkar, V., Kumar, R. V. L., Patel, K., & Kotwal, R. (2024) · Cureus · doi:10.7759/cureus.61766 · Cited by 6
Freudenberg, D. L., Covington, L. P., Young, R. B., Lopez, N. D., Patel, M. V., & MacLaughlin, E. J. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020958245 · Cited by 5
Coke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Insulin Management for Type 2 Diabetes During Ramadan: A Narrative Review for Clinicians
Kieu, A., & Iles, A. N. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220517124752 · Cited by 5
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
“Clinical guidelines have evolved to recommend that pharmacotherapy be selected on the basis of the cardiorenal benefits conferred, alongside considerations such as glucose-lowering efficacy, patient preferences, impact on body weight, contraindications and tolerability.(12,30,46,47)”
BackgroundInfluentialMoreira, R. D. C., Rodrigues, A., Leonardo, B. M., Arabe, D., Santos, R., Cardoso, S. W., Grinsztejn, B. G. J., Veloso, V. G., & Pacheco, A. G. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.12.034 · Cited by 4
Afifah, H., Dewi, I. P., Rachmawati, E., Holidah, D., & Norcahyanti, I. (2024) · JURNAL FARMASIMED (JFM) · doi:10.35451/jfm.v6i2.2051 · Cited by 4
Rural-Urban Disparities in the Uptake of New Diabetes Medications
Zhu, B., Dong, D., Luo, J., & Glied, S. (2024) · Diabetes Spectrum · doi:10.2337/ds23-0075 · Cited by 5
Majd, Z., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., & Abughosh, S. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102295 · Cited by 4
Muthukrishnan, R., Alzaabi, A. M. M. A., Ismail, M., Kandakurthi, P. K., Durairaj, S., Sukumar, S., & Gopal, K. (2025) · Journal of Medicine and Life · doi:10.25122/jml-2024-0277 · Cited by 7
The role of lifestyle factors in type 2 diabetes in children and adolescents: a systematic review
Fortnum, K., Thomas, G., Too, K., Tam, A., Tilley, K., Cairney, J., Healy, G. N., & Gomersall, S. R. (2025) · BMC Public Health · doi:10.1186/s12889-025-23767-0 · Cited by 6
“Pharmacological or lifestyle interventions may be introduced to manage and/or treat type 2 diabetes [15].”
Blonde, L., Fainberg, U., Kaltoft, M. S., Mosenzon, O., Ramesh, C. K., & Rea, R. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14464 · Cited by 5
Self-citationSukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Lifestyle Medicine: An Antidote to Cardiovascular Diseases
Reddy, K. R., & Freeman, A. M. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221130684 · Cited by 4
“” 145 Obesity.”
Müller‐Wieland, D., Freemantle, N., Bonadonna, R. C., Mauquoi, C., Bigot, G., Bonnemaire, M., Gourdy, P., & Mauricio, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01356-3 · Cited by 4
“Long-acting BIAs (i.e., insulin detemir, Gla-100, Gla-300, and insulin deglu-dec) may however be preferred over the inter-mediate-acting NPH insulin, since they show comparable glycaemic control with a reduced risk of hypoglycaemia [1, 2].”
BackgroundMolfetta, S. D., Laviola, L., Natalicchio, A., Leonardini, A., Cignarelli, A., Bonizzoni, E., Acmet, E., & Giorgino, F. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110836 · Cited by 4
Peng, B., Zhang, Y., Cheng, L., Zhang, Y., Lei, X., Leng, W., Wang, J., Wu, S., Wu, X., & Zheng, Y. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/170224 · Cited by 5
The effect of incretin-based drugs on the riks of acute pancreatitis: a review
Czaplicka, A., & Kaleta, B. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01430-6 · Cited by 4
“The American Association of Clinical Endocrinolo - gists and the American College of Endocrinology recom - mend that GLP1RAs should be used with caution in patients with a history of AP and that treatment should be discontin - ued if this complication occurs [49 ].”
Is ‘Cardiopulmonary’ the New ‘Cardiometabolic’? Making a Case for Systems Change in COPD
Hawkins, N. M., Kaplan, A. G., Ko, D. T., Penz, E. D., & Bhutani, M. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00270-2 · Cited by 4
Rayner, D. G., Shah, D. S., Dai, S.-C., Gou, D., Chen, J., Agarwal, A., Mustafa, R. A., Manja, V., Vandvik, P. O., Agoritsas, T., et al. (2025) · BMJ Medicine · doi:10.1136/bmjmed-2025-001369 · Cited by 5
Uzoigwe, C., Radin, M. S., Hamersky, C. M., DeKoven, M., Holt, C., Karkare, S. U., & Polonsky, W. H. (2021) · Quality of Life Research · doi:10.1007/s11136-020-02753-6 · Cited by 5
Resident opinions of diabetes management in training: a survey
Healy, A. M., Uhrig, J. L., Shubrook, J. H., Aung, N. L., & Sadhu, A. (2021) · Journal of Osteopathic Medicine · doi:10.1515/jom-2021-0035 · Cited by 5
Alhussein, N. A., Mahzari, M. M., Aljumaie, N. M., Alosaimi, M., Almansouf, A. S., & Alkahtani, F. (2021) · Cureus · doi:10.7759/cureus.18155 · Cited by 4
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky, B. M., Cummings, D. M., & Powell, J. R. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.03.012 · Cited by 5
Harper, R., Bashan, E., Williams, K. J., Sritharan, S. S., Willis, M., Marriott, D. J., & Hodish, I. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14904 · Cited by 4
“The d-Nav titration follows conventional guidelines in insulin titration without mandating the 50-50 rule; therefore, the resulting basal-bolus ratios are driven solely by real-time adaptation to achieve glycaemic control.(1,4)”
BackgroundMethodInfluentialZhang, X., Yip, T. C., Tse, Y., Hui, V. W., Li, G., Lin, H., Liang, L. Y., Lai, J. C., Lai, M. S., Cheung, J. T. K., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17428 · Cited by 4
Bhattacharyya, S., Saboo, B., Mohit, M., Bhojane, S., Deshmane, R., Chavda, V., Hasnani, D., Jagadeesha, A., & Sikdar, M. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_15_23 · Cited by 4
Mkrtumyan, A. M. (2024) · Terapevticheskii arkhiv · doi:10.26442/00403660.2024.04.202709 · Cited by 5
Zhang, H., Barner, J. C., Moczygemba, L. R., & Rascati, K. L. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.11.1434 · Cited by 6
Fuzzy-Based Application Model and Profile Matching for Recommendation Suitability of Type 2 Diabetic
Wantoro, A., Syarif, A., Muludi, K., & Berawi, K. N. (2021) · International Journal on Advanced Science Engineering and Information Technology · doi:10.18517/ijaseit.11.3.12277 · Cited by 6
“Treatment of medications using Oral and Insulin types [5].”
BackgroundMethodInfluentialMoffatt, E. K., Wargo, R., Johnson, C., & Kawaguchi‐Suzuki, M. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1544 · Cited by 4
Nargesi, A. A., Clark, C. N., Liu, M., Chen, L., Reddy, A., Amodeo, S., Oikonomou, E. K., Suchard, M. A., Lipska, K. J., McGuire, D. K., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(22)02437-8 · Cited by 4
Tsai, C.-J., & Tsao, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111915 · Cited by 4
“Incretin therapy is now recommended as a second-line treatment for type 2 diabetes, according to the newest guidelines [1,2].”
BackgroundErukulapati, R. S., Ganguri, M., Menon, A. S., Ayyagari, U., Jayapaul, M. K., Gurazada, K. C., Nalla, S., Srinath, A., Sampath, S. K., Manohar, S. P., et al. (2023) · Clinical Diabetology · doi:10.5603/dk.a2022.0061 · Cited by 6
Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report
Alromaih, A., Alshamrani, A., Alharbi, B., Alharbi, I., Alharbi, T., Bokhari, S., Elbadawi, H., Almehthel, M. S., Alsaeed, A. H., Alyahia, K., et al. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132017 · Cited by 4
Type 2 diabetes and metabolic surgery guidelines and recommendations should urgently be unified
Halpern, B., & Mancini, M. C. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01603-8 · Cited by 6
SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
Taliercio, J. J., Thomas, G., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20190 · Cited by 4
“5,6 The authors thoroughly highlight the overwhelmingly benefi cial cardiovascular, kidney, and metabolic effects of this new class of medications that is taking many different medical specialties by storm.”
BackgroundAlmaqhawi, A., Alabdulqader, R. A., Alkhteeb, N., Alomair, F. I., Alhassan, S., & Alnajjar, J. S. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s496613 · Cited by 3
“16 The unique dietary restrictions and fasting patterns during Ramadan might influence the pharmacokinetics and pharmacodynamics of GLP-1 agonists.”
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Moosaie, F., Abedinzadeh, S., Rabizadeh, S., Daneshvar, K., Noorafrooz, M., Mojtahedi, F., Deravi, N., Abhari, S. M. F., Ramezani, A., Meysamie, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84993-x · Cited by 4
Trifi, A., Braik, I. B., Galai, H., Azzouz, N., Tlili, B., Mehdi, A., Messaoud, L., Seghir, E., Ouhibi, A., & Abdellatif, S. (2025) · Medicina Intensiva · doi:10.1016/j.medin.2025.502203 · Cited by 3
Lee, J., Rachim, V. P., & Park, S. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.108589 · Cited by 3
Redefining pancreatogenic diabetes mellitus through molecular, imaging, and AI-driven evidence
Rangraze, I. R., El‐Tanani, M., Wali, A. F., Babiker, R., Rabbani, S. A., Matalka, I. I., Satyam, S. M., Арманович, А. А., Hoffmann, K., Ilias, I., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1749805 · Cited by 3
Actualización en el uso de insulinas para el médico de familia
López‐Simarro, F., Cols-Sagarra, C., Bravo, J. J. M., Cañís-Olivé, J., Hernández-Teixidó, C., & Loro, M. B. G. M. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.04.011 · Cited by 7
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
“[11,12] However, in patients who are intolerant to metformin or contraindicated, some GLP‐1RAs are suggested as a first‐line therapy.[12]”
BackgroundAljohani, H. I., Alrubaish, F. S., Alghamdi, W., & Alharbi, F. (2024) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-024-00637-2 · Cited by 3
“Moreover, the results indicated a 32% risk reduction in upper respiratory tract infection and a 65% risk reduction in abdominal pain when using linagliptin compared to a placebo [16, 32].”
Bedoya‐Joaqui, V., Gómez, N. B., Ortiz, R. C., Osorio-Toro, L. M., Muñoz-Lombo, J. P., Cifuentes, C. A. S., García, M. A. M., & Abreu-Lomba, A. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000319 · Cited by 5
“The American Association of Clinical Endocrinologists (AACE), in its 2020 algorithm for glycemic control, made the SGLT2i the second option in the hierarchical order of choice when initiating triple therapy and even in dual therapy after GLP1 analogues (14).”
BackgroundCardiovascular Disease in Patients with Diabetes: A Comparison of Professional Society Guidelines
Sarkar, S., Salazar, I. M. C., Tibuakuu, M., & Blumenthal, R. S. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210820105514 · Cited by 3
Charbonnel, B. H., Chen, H., Cid‐Ruzafa, J., Cooper, A., Fenici, P., Gomes, M. B., Saraiva, G. L., Medina, J., Nicolucci, A., Shestakova, M. V., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14842 · Cited by 3
“Global guidelines, including those from the European Association for the Study of Diabetes/American Diabetes Association, Diabetes Canada, the World Health Organization (WHO), and the International Diabetes Federation (IDF), suggest selecting second-line glucoselowering treatments based on patient characteristics such…”
BackgroundMartínez, I. M. P., Pastor, A. M., García, J. J. G., Barquilla-García, A., Martín, V., Pérez, R. M., & Divisón, J. A. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.07.001 · Cited by 3
The case for screening for diabetes distress, depression, and anxiety
Michot, A. P., Evans, T. L., Vasudevan, M. M., Bradford, A. M., Hundt, N. E., Christie, I. C., True, G., & Kunik, M. E. (2024) · Journal of Health Psychology · doi:10.1177/13591053241241841 · Cited by 3
“The American Association of Clinical Endocrinologists/American College of Endocrinology (Garber et al., 2020) and the Department of Veterans Affairs/Department of Defense (2023) mention the need for a mental health assessment for those with DM but do not elaborate.”
A Case Report of Acute Pancreatitis in Food-Induced Anaphylaxis
Wiese, J., Dakkak, B., Ugonabo, O. S., El-Dallal, M., & Frandah, W. (2024) · Cureus · doi:10.7759/cureus.71017 · Cited by 3
Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes
Sabbour, H. M., Almahmeed, W. A., Alawadi, F., Shehab, A. M., Zubaidi, A. A., Bashier, A. M., Ghulam, A. R., Rashid, F., Zaky, H., Kassem, H. H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395630 · Cited by 4
Xu, Y., Wu, S., Niu, J., Li, M., Lu, J., Wang, W., He, J., Solomon, H. A., Bi, Y., & Ning, G. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13071 · Cited by 3
Jiménez-Montero, J. G., Solórzano, M. L. C., & Barakat, M. V. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1068 · Cited by 3
“…of treatment modification patients treated with human insulins were switched to insulin analogues and oral agents including dipeptidyl peptidase-4 inhibitors (DPP-4i) (n=11), sodium-glucose transporters inhibitors (SGLT2i) (n=7) or GLP-1 receptor agonists (n=1) were added as recommended [24-25].”
InfluentialGill, G. S., Latif, A., Hilleman, D. E., Lavie, C. J., & Alla, V. M. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100878 · Cited by 4
The role of icosapent ethyl in cardiovascular risk reduction
Goldenberg, R., CHENG, A. Y. Y., Gilbert, J. D., Lonn, E., Pedersen, S. D., & Verma, S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000873 · Cited by 3
“Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.”
MethodInfluentialQuality of Diabetes Care in the USA
Alencherry, B., & Bruemmer, D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01503-5 · Cited by 4
WANGNOO, S. K., Shunmugavelu, M., Reddy, S. V. B., Negalur, V. B., Godbole, S. V., Dhandhania, V. K., Krishna, N., & Gaurav, K. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100102 · Cited by 4
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
“Current clinical practice guidelines support the use of metformin as first-line therapy in patients with T2DM due to its favorable effects on HbA1c and weight, as well as its overall safety profile [6,7].”
BackgroundInfluentialA Value-of-Information Framework for Personalizing the Timing of Surveillance Testing
Bansal, A., Heagerty, P. J., Inoue, L. Y. T., Veenstra, D. L., Wolock, C. J., & Basu, A. (2021) · Medical Decision Making · doi:10.1177/0272989x211049213 · Cited by 3
“Frequent surveillance testing using biomarkers is recommended and routinely conducted for several diseases, including cancer and diabetes.(10) However, frequent testing involves tradeoffs.”
BackgroundJang, J., Colletti, A. A., Ricklefs, C., Snyder, H. J., Kardonsky, K., Duggan, E. W., Umpierrez, G. E., & O’Reilly-Shah, V. N. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01421-4 · Cited by 3
“Fortunately, societies such as the American Diabetes Association (ADA) and American Association of Clinical Endocrinology (AACE) offer annually updated evidencebased guidelines for best practices for the management of diabetes [3, 5].”
BackgroundSelf-citationDas, A. K., Gandhi, P., Saboo, B., Reddy, S. C., Chawla, R., Zargar, A. H., KOVIL, R. R., Chawla, M. S., Sharma, S., Gupta, S., et al. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2378_20 · Cited by 7
Clements, J. N. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001248 · Cited by 3
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
“SECOND-GENERATION BASAL INSULINS: WHY PHARMACOKINETIC/PHARMACODYNAMIC PROFILES MATTER Guideline recommendations call for use of BI analogues, which carry a lower risk of hypoglycaemia compared with neutral protamine Hagedorn insulin (NPH) [1, 2, 26].”
BackgroundDiabetes: how to manage cardiovascular risk in secondary prevention patients
Anderson, S. L., & Marrs, J. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-10-1 · Cited by 3
Martínez, I. M. P., Pastor, A. M., García, J. J. G., Barquilla-García, A., Martín, V., Pérez, R. M., & Divisón, J. A. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.04.008 · Cited by 3
Pantalone, K. M., Rajpathak, S. N., Ji, X., Jin, J., Weiss, T., Bauman, J. M., Radivoyevitch, T., Kattan, M. W., Zimmerman, R. S., & Misra‐Hebert, A. D. (2022) · Diabetes Spectrum · doi:10.2337/ds22-0031 · Cited by 3
“Despite clinical practice guidelines recommending frequent A1C monitoring and aggressive escalation of antidiabetes therapies every 3 months until glycemic targets are reached (1,2), therapy intensification in patients with uncontrolled type 2 diabetes is often inappropriately delayed (3–7).”
BackgroundAlhaj, O., & Afandi, B. O. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0042-1755440 · Cited by 3
Abu‐Alfa, A. K., Atallah, P., Azar, S. T., Dagher, E., Echtay, A. S., Amm, M., Hazkial, H. G., Kassab, R., Medlej, R., & Mohamad, M. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01340-x · Cited by 4
“AACE/ACE, 2020 [64] Independently of glycemic control, if established ASCVD or high risk ASCVD, CKD, or HFrEF,”
BackgroundFan, Z., Cui, L., Ye, Y., Li, S., & Deng, N. (2022) · JMIR Medical Informatics · doi:10.2196/42664 · Cited by 4
“…(2017) Edition [22], National guidelines for the prevention and control of diabetes in primary care (2018) [23], the comprehensive type 2 diabetes management algorithm [24], Management of Hyperglycemia in Type 2 Diabetes [25], and Diabetes Canada Clinical Practice Guidelines Expert Committee [26].”
BackgroundArif, S. A., Lakada, I. Y., Fawaz, Z., Abuzir, J., & O’Donnell, E. P. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i2.5243 · Cited by 3
Ponomareva, E., Schmerold, L. M., Srinivas, S. S. S., Preblick, R., Park, S., Wilson, L., & Revel, A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277058 · Cited by 3
“Despite new antidiabetic drugs, the progressive nature of the disease necessitates the dependency on exogenous insulin in many patients 15–17 .”
BackgroundTornaghi, M., Redha, A. A., Rondanelli, M., & Perna, S. (2023) · PharmaNutrition · doi:10.1016/j.phanu.2023.100363 · Cited by 4
Hachem, M., Hearn, T., Kelly, R. D., Eer, A., Moore, B., Sommerville, C., Atkinson‐Briggs, S., Twigg, S. M., Freund, M., O'Neal, D. N., et al. (2024) · Trials · doi:10.1186/s13063-024-08267-7 · Cited by 4
“CGM is recognised by peak diabetes bodies for improving glycaemic management, particularly for people with type 1 diabetes [17–19] with growing evidence of its use for type 2 diabetes.”
BackgroundTrends in premature mortality from diabetes mellitus in Costa Rica in the period 2000–2020
Quesada, J. A., Carratalá‐Munuera, C., Carbonell-Soliva, Á., Aparicio, J. C. S., Fernández, J. G., Salazar‐Sánchez, L., Gil-Guillén, V. F., López‐Pineda, A., Nouni-García, R., & Orozco‐Beltrán, D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2135865 · Cited by 4
“The latest international clinical practice guidelines on the management of type 2 diabetes recommend oral hypoglycemic agents such as metformin as first-line therapy [30,31].”
BackgroundAn Expert Opinion on the Management of Type 2 Diabetes Mellitus in Children and Adolescents
Rajput, R., Jha, S. K., Panda, J. K., Subrahmanyam, A. K., & Das, S. (2021) · Journal of Diabetology · doi:10.4103/jod.jod_71_21 · Cited by 3
Kumar, A., Sharma, S., Gupta, A., Dasgupta, A., Asirvatham, A. J., Talwalkar, P., Das, A., & Mohan, V. (2020) · Journal of Diabetology · doi:10.4103/jod.jod_59_20 · Cited by 3
Weir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Glycemic Targets and Glucose Monitoring
Oser, T. K., & Oser, S. M. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.002 · Cited by 3
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
Ferreira, A. C., Moreira, R. D. C., Coelho, L. E., Jalil, E. M., Benseñor, I. M., Friedman, R. K., Monteiro, L., Eksterman, L. F., Moreira, R. I., Cardoso, S. W., et al. (2023) · Transgender Health · doi:10.1089/trgh.2022.0062 · Cited by 2
Hasan, A., Ahmed, G. M. S., Hady, B. M. A., Ahmed, I. H., Saghier, E. O. A. E., Sayed, M. F. M. E., Azel, L. H., Mohamed Marwa, A., Saleh, O. I., Taha, R. I., et al. (2023) · Bioactive Compounds in Health and Disease · doi:10.31989/bchd.v6i11.1235 · Cited by 2
“Better glycemic control may alleviate these conditions [24].”
BackgroundHong, L., Sun, Y., Lu, X., & Xu, X. (2025) · Biomedical Reports · doi:10.3892/br.2025.1939 · Cited by 2
Cao, M., Lin, Q., Lin, L., Zhang, W., & Zhang, L. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-54743 · Cited by 2
Zhou, L., Duanmu, W., Tan, F., Gu, X., Che, H., & Yin, W. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13377-2 · Cited by 2
Genie, M. G., & Ngorsuraches, S. (2025) · Value in Health · doi:10.1016/j.jval.2025.10.011 · Cited by 2
Chen, K., Ma, H., Wang, Y., Li, D., Li, J., Huang, Y. L., & Huang, M. (2025) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-025-01402-0 · Cited by 2
“With advances in continuous glucose monitoring (CGM), current systems provide near-continuous interstitial glucose measurements, capturing hyperglycemia, hypoglycemia, and variability, and yielding standardized indices commonly used in diabetes management [9–11].”
Li, X., Xia, T., Landsbergis, P. A., Wong, I. S., & Li, J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101379 · Cited by 2
“Current U.S. secondary prevention guidelines for CMD, including those for chronic coronary disease [55], stroke [56], hypertension [57], and diabetes [58], largely overlook occupational risk factors despite robust evidence linking workplace exposures to worse prognosis.”
Şirikçi, V., & Fındıklı, H. A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1751404 · Cited by 2
“The HbA1c interval of approximately 8.0%–8.5% represents a therapeutically ambiguous “glycemic gray zone,” in which the pace of cardiovascular risk progression driven by atherogenic dyslipidemia and the need for intensified lipid management remain unclear (9, 10).”
InfluentialCarga económica de la hipercolesterolemia en población con alto riesgo cardiovascular en México
Gasca-Pineda, R., Osorio-Hernández, M., Mehta, R., Escobedo, J., & Narváez-Oríani, C. A. (2023) · Archivos de cardiología de México · doi:10.24875/acm.22000195 · Cited by 4
Metadata
- Authors
- Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., Garvey, W. T., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Perreault, L., Rosenblit, P. D., Samson, S., & Umpierrez, G. E.
- Affiliations
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California San Diego (US)
- Beth Israel Deaconess Medical Center (US)
- Kaiser Permanente (US)
- Ochsner Health System (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- University of Miami (US)
- Washington University in St. Louis (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Colorado Anschutz (US)
- University of California, Irvine (US)
- Emory University (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 26
- Issue
- 1
- Pages
- 107-139
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3004838676
- Cited by
- 598
- References
- 300
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 80 · 2023: 104 · 2022: 146 · 2021: 125 · 2020: 81
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes management, glycemic control, cardiovascular risk, atherosclerotic cardiovascular disease, chronic kidney disease, diabetic ketoacidosis, obstructive sleep apnea, dyslipidemia, obesity, GLP-1 receptor agonists, SGLT2 inhibitors, insulin therapy, continuous glucose monitoring, self-monitoring of blood glucose
- MeSH terms
- Proprotein Convertase 9, Endocrinologists, Algorithms, Blood Glucose, Diabetes Mellitus, Type 2, Humans, United States, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.